CymaBay Therapeutics (CBAY) Rating Lowered to Hold at BidaskClub

Share on StockTwits

CymaBay Therapeutics (NASDAQ:CBAY) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, BidAskClub reports.

Several other equities analysts have also recently weighed in on the company. Piper Jaffray Companies set a $30.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price target on shares of CymaBay Therapeutics in a research report on Friday, February 1st. Roth Capital reiterated a “buy” rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 19th. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Friday, February 15th. Finally, Leerink Swann started coverage on CymaBay Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $22.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $19.63.

Shares of NASDAQ CBAY opened at $12.07 on Thursday. The firm has a market capitalization of $717.80 million, a PE ratio of -9.58 and a beta of 1.84. CymaBay Therapeutics has a fifty-two week low of $6.31 and a fifty-two week high of $15.00.

In related news, Director Carl Goldfischer sold 11,675 shares of the business’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $9.02, for a total transaction of $105,308.50. Following the completion of the transaction, the director now directly owns 2,335 shares in the company, valued at $21,061.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.50% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in CymaBay Therapeutics by 16.3% during the fourth quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock worth $40,622,000 after buying an additional 722,753 shares in the last quarter. Eagle Asset Management Inc. grew its position in CymaBay Therapeutics by 0.3% during the fourth quarter. Eagle Asset Management Inc. now owns 2,852,973 shares of the biopharmaceutical company’s stock worth $22,452,000 after buying an additional 8,207 shares in the last quarter. Vanguard Group Inc grew its position in CymaBay Therapeutics by 4.1% during the third quarter. Vanguard Group Inc now owns 2,789,188 shares of the biopharmaceutical company’s stock worth $30,903,000 after buying an additional 109,989 shares in the last quarter. Vanguard Group Inc. grew its position in CymaBay Therapeutics by 4.1% during the third quarter. Vanguard Group Inc. now owns 2,789,188 shares of the biopharmaceutical company’s stock worth $30,903,000 after buying an additional 109,989 shares in the last quarter. Finally, Foresite Capital Management IV LLC grew its position in CymaBay Therapeutics by 30.0% during the fourth quarter. Foresite Capital Management IV LLC now owns 2,631,258 shares of the biopharmaceutical company’s stock worth $20,708,000 after buying an additional 607,889 shares in the last quarter. Institutional investors and hedge funds own 98.00% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

See Also: Diversification For Individual Investors

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.